Kevin Lonabaugh

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 5

Top Topics

Low Density Lipoprotein

Smoking Cessation

Cystic Fibrosis

Top Venues

Pharmacotherapy

Pediatric pulmonology

This page only lists publications with an associated author ORCID identifier.

Publications

Kevin Lonabaugh, Galvin Li, Rhonda List, Reyna Huang, Amber James, Andrew Barros, Lindsay Somerville, Dana Albon
Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis. Pharmacotherapy 44 (3) (2024)
Kevin Lonabaugh, Galvin Li, Rhonda List, Reyna Huang, Amber James, Andrew Barros, Lindsay Somerville, Dana Albon
Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis. Pharmacotherapy 44 (3) (2024)
Amber James, Galvin Li, Rhonda List, Kevin Lonabaugh, Aaron D Smith, Andrew Barros, Lindsay Somerville, Dana Albon
Analysis of iron status after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis. Pediatric pulmonology (2023)
Kevin Lonabaugh, Galvin Li, Rhonda List, Reyna Huang, Amber James, Andrew Barros, Lindsay Somerville, Dana Albon
Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis. Pharmacotherapy (2023)
Kevin Lonabaugh, Galvin Li, Rhonda List, Reyna Huang, Amber James, Andrew Barros, Lindsay Somerville, Dana Albon
Real world study on elexacaftor-tezacaftor-ivacaftor impact on cholesterol levels in adults with cystic fibrosis. Pharmacotherapy (2023)